{
    "clinical_study": {
        "@rank": "90522", 
        "arm_group": [
            {
                "arm_group_label": "HSL(Totilac)", 
                "arm_group_type": "Experimental", 
                "description": "Hypertonic Sodium Lactate"
            }, 
            {
                "arm_group_label": "6% HES (Voluven)", 
                "arm_group_type": "Active Comparator", 
                "description": "6% Hydroxyethyl Starch"
            }
        ], 
        "brief_summary": {
            "textblock": "The choice of fluid therapy is controversial in cardiac surgery. Numerous studies have shown\n      that colloid is better as compared to crystalloids. Several previous studies have\n      demonstrated that Hypertonic Sodium Lactate (HSL) administration during cardiac surgery\n      shows a promising effect. This study aims to compare hemodynamic effects and fluid balance\n      of HSL with 6% Hydroxy  Ethyl Starch (HES)."
        }, 
        "brief_title": "Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients", 
        "completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objectives of this prospective, randomized and open-label study are as follows:\n\n        -  To evaluate the clinical efficacy of Hypertonic Sodium Lactate (HSL) in comparison with\n           6% HES to maintain hemodynamic stability in intra CABG patients related to hemodynamic\n           status and Body fluid balance.\n\n        -  To assess the safety of HSL in intra CABG patients related to defined laboratory\n           parameters clinical adverse events which occur during the trial.\n\n      Subjects meeting enrolment criteria will be randomly assigned to HSL or 6%HES treatment\n      groups.\n\n      Assessment of comparability will be done by unpaired student t-test or Chi-Square test or by\n      a two-way ANOVA for repeated measures followed by post-hoc analysis when significant\n      difference is found within the two groups.\n\n      The hypothesis tested is that HSL is effective in intra CABG surgery patients, requiring\n      less volume with better cardiac index, as compared to 6% HES."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 45-80 years.\n\n          -  CABG patients with on or off pump procedure.\n\n          -  Ejection fraction <50%\n\n          -  Patients who have given their written informed consent.\n\n        Exclusion Criteria:\n\n          -  Combined operations(surgeries)\n\n          -  Patients with severe arrhythmia (VT, AF rapid response, heart block) and severe\n             hemodynamic imbalance.\n\n          -  Severe bleeding and/or re-operation.\n\n          -  Hypernatremia> 155 mmol/L\n\n          -  Severe liver failure: SGOT and SGPT more than twice normal.\n\n          -  Severe renal failure: creatinine more than 2 mg%.\n\n          -  Patients with major diseases such as cancer, etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654653", 
            "org_study_id": "LB.05.01.1.4.0.70"
        }, 
        "intervention": [
            {
                "arm_group_label": "HSL(Totilac)", 
                "description": "Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.", 
                "intervention_name": "Hypertonic sodium lactate", 
                "intervention_type": "Drug", 
                "other_name": "Totilac"
            }, 
            {
                "arm_group_label": "6% HES (Voluven)", 
                "description": "Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly", 
                "intervention_name": "6% Hydroxy Ethyl Starch", 
                "intervention_type": "Drug", 
                "other_name": "Voluven"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart disease", 
            "cardiac surgery", 
            "CABG", 
            "Totilac", 
            "Voluven", 
            "6% HES"
        ], 
        "lastchanged_date": "July 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jakarta", 
                    "country": "Indonesia", 
                    "zip": "11420"
                }, 
                "name": "National Cardiovascular Center Harapan Kita"
            }
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase , Prospective, Randomized, Open-label Study to Compare the Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG (Coronary Artery Bypass Grafting) Patients", 
        "overall_official": {
            "affiliation": "National Cardiovascular Center Harapan Kita, Indonesia", 
            "last_name": "Cindy E Boom, PhD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "\u2022 Evaluation of efficacy of Hypertonic Sodium Lactate against 6% HES to maintain hemodynamic stability in intra CABG patients:\nHemodynamic status (CI, MAP, PVR/PVRI, SVR/SVRI, CVP, PAM, PAW, HR).\nBody fluid balance (urinary output; total fluid loss including urine and hemorrhage; total fluid infusion including HSL and 6% HES, blood product and other fluids).", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Assessed from baseline till upto end of surgery(mean duration of surgery was 372.47 \u00b1 122.82 min  in HSLgroup vs 380.61 \u00b1 82.08 min  in HES group"
            }, 
            {
                "description": "Assess safety of HSL in intra CABG patients:\nLab parameters: Hb, HCT, Na,K, Cl, Mg, lactate, glucose, and arterial blood gas.\nAdverse events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed from baseline till upto end of surgery(mean duration of surgery was 372.47 \u00b1 122.82 min  in HSLgroup vs 380.61 \u00b1 82.08 min  in HES group"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654653"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Innogene Kalbiotech Pte. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Innogene Kalbiotech Pte. Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}